RIGI and neoplasm: Inthis regard, our investigations provide a preclinical benchmark forevaluating systemically administered RIG-I agonists and their carriers.It is important to recognize that even the most promising nanoparticles,LNPs or otherwise, deliver only a small fraction of their nucleicacid cargo to tumor sites and primarily distribute to the liver and/orspleen, depending on nanoparticle properties and/or composition.